Cinqair (reslizumab) is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa).

Cinqair is specifically indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.

Cinqair is supplied as a solution for intravenous administration.

Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Average rating:  
 0 reviews
  • Cinqair
  • Adverse effects associated with the use of Cinqair may include, but is not limited to, the following:

    oropharyngeal pain
    Cinqair comes with a black box warning of the potential for anaphylaxis.
  • The recommended dose is 3 mg/kg once every 4 weeks administered by intravenous infusion over 20-50 minutes.